Frontiers in cancer prevention research

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5649-5655

  Sabichi, Anita L ^a   Demierre, Marie France ^b   Hawk, Ernest T ^c   Lerman, Caryn E ^d   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BCG VACCINE; BIOLOGICAL MARKER; CURCUMIN; CYTOTOXIC AGENT; DICLOFENAC; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FINASTERIDE; FLUOROURACIL; GREEN TEA EXTRACT; HEPATITIS B VACCINE; ISOTRETINOIN; MINERAL; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; POLYPHENOL DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEINASE INHIBITOR; RESVERATROL; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULINDAC; TAMOXIFEN; TRITERPENOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; VITAMIN;

ADENOMA; BEHAVIORAL SCIENCE; BLADDER CANCER; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON POLYP; CONFERENCE PAPER; DRUG TARGETING; EARLY DIAGNOSIS; ENERGY BALANCE; GENETICS; HUMAN; LIVER CANCER; MEDICAL RESEARCH; NUTRITION; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SKIN CANCER;

CHEMOPREVENTION; HUMANS; NEOPLASMS;

EID: 0141731350     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (128)

1. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins. J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. (Bethesda), 90: 1371-1388, 1998.
2. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946-1952, 2000.
3. Thompson, I. A., Goodman, P. J., Tangen, C. M., Lucia, S. M., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., Carlin, S. M., Ryan, A., Szczepanek, C. M., Crowley, J. J., and Coltman, C. A. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med., 349: 213-222, 2003.
4. Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., Snover, D. C., Church, T. R., Allen, J. I., Beach, M., Beck, G. J., Bond, J. H., Byers, T., Greenberg, E. R., Mandel, J. S., Marcon, N., Mott, L. A., Pearson, L., Saibil, F., and van Stolk, R. U. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med., 348: 891-899, 2003.
5. Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., Steinbach, G., and Schilsky, R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med., 348: 883-890, 2003.
6. Sudbo, J., Kildal, W., Risberg, B., Koppang, H. S., Danielsen, H. E., and Reith, A. DNA content as a prognostic marker in patients with oral leukoplakia. New Engl. J. Med., 344: 1270-1278, 2001.
7. Lippman, S. M., and Hong, W. K. Molecular markers of the risk of oral cancer. N. Engl. J. Med., 344: 1323-1326, 2001.
8. Nowak, M. A., Komarova, N. L., Sengupta, A., Jallepalli, P. V., Shih, L-M., Vogelstein, B., and Lengauer, C. The role of chromosomal instability in tumor initiation. Proc. Natl. Acad. Sci. USA, 99: 16226-16231, 2002.
9. Jones, P. A., and Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3: 415-428, 2002.
10. Mao, L., Lee, J. S., Fan, Y. H., Ro, J. Y., Batsakis, J. G., Lippman, S. M., Hittelman, W., and Hong, W. K. Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and its value in cancer risk assessment. Nat. Med., 2: 682-685, 1996.
11. Braakhuis, B. J. M., Tabor, M. P., Kummer, J. A., Leemans, C. R., and Brakenhoff, R. H. A genetic explanation of Slaughter's concept of field cancerization. Cancer Res., 63: 1727-1730, 2003.
12. Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., and Yasui, Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. (Bethesda), 93: 1054-1061, 2001.
13. Makridakis, N. M., Ross, R. K., Pike, M. C., Crocitto, L. E., Kolonel, L. N., Henderson, B. E., and Reichardt, J. K. V. A missense substitution in the SRD5A2 gene is associated with prostate cancer in African-American and Hispanic men in Los Angeles. Lancet, 354: 975-978, 1999.
14. McKean-Cowdin, R., Feigelson, H. S., Pike, M. C., Coetzee, G. A., Kolonel, L. N., and Henderson, B. E. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res., 61: 848-849, 2001.
15. Wei, Q., Cheng, L., Amos, C. I., Wang, L. E., Guo, Z., Hong, W. K., and Spitz, M. R. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J. Natl. Cancer Inst. (Bethesda), 92: 1764-1772, 2000.
16. Slattery, M. L., Curtin, K., Ma, K., Schaffer, D., Potter, J., and Samowitz, W. GSTM-1 and NAT2 and genetic alterations in colon tumors. Cancer Causes Control, 13: 527-534, 2002.
17. Ulrich, C. M., Bigler, J., Bostick, R., Fosdick, L., and Potter, J. D. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res., 62: 3361-3364, 2002.
18. Izzo, J. G., Papadimitrakopoulou, V. A., Liu, D. D., den Hollander, P. L., Babenko, I. M., Keck, J., El-Naggar, A. K., Shin, D. M., Lee, J. J., Hong, W. K., and Hittelman, W. N. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J. Natl. Cancer Inst. (Bethesda), 95: 198-205, 2003.
19. Bigler, J., Whitton, J., Lampe, J. W., Fosdick, L., Bostick, R. M., and Potter, J. D. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res., 61: 3566-3569, 2001.
20. King, M. C., Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K., Tait, J., Ford, L., Dunn, B. K., Costantino, J., Wickerham, L., Wolmark, N., and Fisher, B. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. J. Am. Med. Assoc., 286: 2251-2256, 2001.
21. Lerman, C., and Niaura, R. Applying genetic approaches to the treatment of nicotine dependence. Oncogene, 21:7412-7420, 2002.
22. Weitzel, J. N., and McCahill, L. E. The power of genetics to target surgical prevention. N. Engl. J. Med., 344: 1942-1944, 2001.
23. Haber, D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N. Engl. J. Med., 346: 1660-1662, 2002.
24. Stoutjesdijk, M. J., and Barentsz, J. O. Prophylactic mastectomy in carriers of BRCA mutations. N. Engl. J. Med., 345: 1499-5000, 2001.
25. Berry, D. A., Iversen, E. S., Jr., Gudbjartsson, D. F., Hiller, E. H., Garber, J. E., Peshkin, B. N., Lerman, C., Watson, P., Lynch, H. T., Hilsenbeck, S. G., Rubinstein, W. S., Hughes, K. S., and Parmigiani, G. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J. Clin. Oncol., 20: 2701-2712, 2002.
26. Wu, X., Lippman, S. M., Lee, J. J., Zhu, Y., Wei, Q. V., Thomas, M., Hong, W. K., and Spitz, M. R. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res., 62: 2813-2818, 2002.
27. Vourlekis, J. A., and Szabo, E. Predicting success in cancer prevention trials. J. Natl. Cancer Inst. (Bethesda), 95; 178-179, 2003.
28. Liang, Z., Lippman, S. M., Kawabe, A., Shimada, Y., and Xu, X-C. Identification of benzo[a]pyrene diol epoxide-binding DNA fragments using DNA-immunoprecipitation technique. Cancer Res., 63: 1470-1474, 2003.
29. Traverso, G., Shuber, A., Levin, B., Johnson, C., Olsson, L., Hamilton, S. R., Boynton, K., Kinzler, K. W., and Vogelstein, B. Detection of APC mutations in fecal DNA of patients with colorectal tumors. N. Engl. J. Med., 346: 311-320, 2002.
30. Mambo, E., Gao, X., Cohen, Y., Guo, Z., Talalay, P., and Sidransky, D. Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc. Natl. Acad. Sci. USA, 100: 1838-1843, 2003.
31. Petricoin, E. F., III, Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., and Liotta, L. A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 359: 572-577, 2002.
32. O'Shaughnessy, J. A., Kelloff, G. J., Gordon, G. B., Dannenberg, A. J., Hong, W. K., Fabian, C. J., Sigman, C. C., Bertagnolli, M. M., Stratton, S. P., Lam, S., Nelson, W. G., Meyskens, F. L., Alberts, D. S., Follen, M., Rustgi, A. K., Papadimitrakopoulou, V., Scardino, P. T., Gazdar, A. F., Wattenberg, L. W., Sporn, M. B., Sakr, W. A., Lippman, S. M., and Von Hoff, D. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res., 8: 314-346, 2002.
33. 2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus. Cancer Res., 63: 4211-4217, 2003.
34. Mao, L., El-Naggar, A. K., Papadimitrakopoulou, V., Shin, D. M., Shin, H. C., Fan, Y., Zhou, X., Clayman, G., Lee, J. J., Lee, J. S., Hittelman, W. N., Lippman, S. M., and Hong, W. K. Phenotype and genotype in advanced premalignant head and neck lesions after chemopreventive therapy. J. Natl. Cancer Inst. (Bethesda), 90: 1545-1551, 1998.
35. Lippman, S. M., Benner, S. E., and Hong, W. K. Cancer chemoprevention. J. Clin. Oncol., 12: 851-873, 1994.
36. Lippman, S. M., Lee, J. J., and Sabichi, A. L. Cancer chemoprevention: progress and promise. J. Natl. Cancer Inst. (Bethesda), 90: 1514-1528, 1998.
37. Gupta, R. A., and DuBois, R. N. Combinations for cancer prevention. Nature Med., 6: 974-975, 2000.
38. Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., and Aggarwal, B. B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene, 20: 7597-7609, 2001.
39. Clifford, J. L., Yang, X., Walch, E., Wang, M., and Lippman, S. M. Dominant negative STAT2 protein: stable expression blocks interferon α action in skin squamous cell carcinoma cells. Mol. Cancer Ther., 2: 453-459, 2003.
40. Liu, Y., Ludes-Meyers, J., Zhang, Y., Munoz-Medellin, D., Kim, H. T., Lu, C., Ge, G., Schiff, R., Hilsenbeck, S. G., Osborne, C. K., and Brown, P. H. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene, 21: 7680-7689, 2002.
41. Nelson, W. G., DeMarzo, A. M., and Isaacs, W. B. Mechanisms of disease: prostate cancer. N. Engl. J. Med., 349: 366-381, 2003.
42. Rudin, C. M., Cohen, E. E. W., Papadimitrakopoulou, V. A., Solverman, S., Jr., Recant, W., El-Naggar, A. K., Stenson, K., Lippman, S. M., Hong, W. K., and Vokes, E. E. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J. Clin. Oncol., in press, 2003.
43. Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L., and Matrisian, L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA, 94: 1402-1407, 1997.
44. Deguchi, A., Soh, J-W., Li, H., Pamukcu, R., Thompson, W. J., and Weinstein, I. B. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G1. Mol. Cancer Ther., 1: 803-809, 2002.
45. Shureiqi, I., Jiang, W., Zuo, X., Wu, Y., Stimmel, J. B., Leesnitzer, L. M., Morris, J. S., Fan, H-Z., Fischer, S. M., and Lippman, S. M. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulated PPAR-δ to induce apoptosis in colorectal cancer cells. Proc. Natl. Acad. Sci. USA, 100: 9968-9973, 2003.
46. Johnstone, R. W., Ruefli, A. A., and Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108: 153-164, 2002.
47. Kavanaugh, C. J., Desai, K. V., Calvo, A., Brown, P. H., Couldrey, C., Lubet, R., and Green, J. E. Pre-clinical applications of transgenic mouse mammary cancer models. Transgenic Res., 11: 617-633, 2002.
48. Bachelor, M. A., Silvers, A. L., and Bowden, G. T. The role of p38 in UVA-induced cyclooxygenase-2 expression in the human keratinocyte cell line, HaCaT. Oncogene, 21: 7092-7099, 2002.
49. Lu, Y. P., Lou, Y. R., Xie, J. G., Peng, Q. Y., Liao, J., Yang, C. S., Huang, M. T., and Conney, A. H. Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc. Natl. Acad. Sci. USA, 99: 12455-12460, 2002.
50. Suh, N., Roberts, A. B., Birkey Reffey, S., Miyazono, K., Itoh, S., ten Dijke, P. P., Heiss, E. H., Place, A. E., Risingsong, R., Williams, C. R., Honda, T., Gribble, G. W., and Sporn, M. B. Synthetic triterpenoids enhance transforming growth factor β/Smad signaling. Cancer Res., 63: 1371-1376, 2003.
51. Huang, C., Huang, Y., Li, J., Hu, W., Aziz, R., Tang, M. S., Sun, N., Cassady, J., and Stoner, G. D. Inhibition of benzo(a)pyrene diol-epoxide-induced transactivation of activated protein 1 and nuclear factor κB by black raspberry extracts. Cancer Res., 62: 6857-6863, 2002.
52. Chun, K. H., Kosmeder, J. W., II, Sun, S., Pezzuto, J. M., Lotan, R., Hong, W. K., and Lee, H. Y. Effects of deguelin on the phosphatidylinositol 3-kinase/akt pathway and apoptosis in premalignant human bronchial epithelial cells. J. Natl. Cancer Inst. (Bethesda), 95: 291-302, 2003.
53. Leob, L. A. A mutator phenotype in cancer. Cancer Res., 61: 3230-3239, 2001.
54. Lippman, S. M., and Hong, W. K. Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development Clin. Cancer Res., 8: 314-346, 2002. Clin. Cancer Res., 8: 305-313, 2002.
55. Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., and Hong, W. K. Head and neck Cancer. N. Engl. J. Med, 328: 184-194, 1993.
56. Lippman, S. M., Batsakis, J. G., Toth, B. B., Weber, R. S., Lee, J. J., Martin, J. W., Hays, G. L., Goepfert, H., and Hong, W. K. Comparison of low-dose isotretinoin with β-carotene to prevent oral carcinogenesis. N. Engl. J. Med., 328: 15-20, 1993.
57. Lotan, R., Xu, C., Lippman, S. M., Ro, J. Y., Lee, J. S., Lee, J. J., and Hong, W. K. Suppression of retinoic acid receptor β in oral premalignant lesions and its upregulation by isotretinoin. N. Engl. J. Med., 332: 1405-1410, 1995.
58. Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., Peters, L. J., Dimery, I. W., Brown, B. W., and Goepfert, H. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 323: 795-801, 1990.
59. Chang, M. H., Chen, C. J., Lai, M. S., Hsu, H. M., Wu, T. C., Kong, M. S., Liang, D. C., Shau, W. Y., and Chen, D. S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med., 336: 1855-1859, 1997.
60. Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., Kardinal, C. G., Kavanah, M. T., Fehrenbacher, L., and Oishi, R. H. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, 353: 1993-2000, 1999.
61. Lippman, S. M., and Brown, P. H. Tamoxifen prevention of breast cancer: an instance of the fingerpost. J. Natl. Cancer Inst. (Bethesda), 91: 1809-1819, 1999.
62. First results from the International Breast Cancer Intervention Study (IBIS-I). A randomised prevention trial. Lancet, 360: 817-824, 2002.
63. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
64. Giardiello, F. M., Yang, V. W., Hylind, L. M., Krush, A. J., Petersen, G. M., Trimbath, J. D., Piantadosi, S., Garrett, E., Geiman, D. E., Hubbard, W., Offerhaus, G. J. A., and Hamilton, S. R. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med., 346: 1054-1059, 2002.
65. Baron, J. A., Beach, M., Mandel, J. S., van Stolk, R. U., Haile, R. W., Sandler, R. S., Rothstein, R., Summers, R. W., Snover, D. C., Beck, G. J., Bond, J. H., Greenberg, E. R., Frankl, H., and Pearson, L. Calcium supplements for the prevention of colorectal adenomas. N. Engl. J. Med., 340: 101-107, 1999.
66. Zur Hausen, H. Cervical carcinoma and human papillomavirus: on the road to preventing major human cancer. J. Natl. Cancer Int. (Bethesda), 93: 252-253, 2001.
67. Finn, O. J., and Forni, G. Prophylactic cancer vaccines. Curr. Opin. Immunol., 14: 172-177, 2002.
68. Chung, M. A., Luo, Y., O'Donnell, M., Rodriguez, C., Heber, W., Sharma, S., and Chang, H. R. Development and preclinical evaluation of a Bacillus Calmette-Guerin-MUC1-based novel breast cancer vaccine. Cancer Res., 63: 1280-1287, 2003.
69. Decensi, A., Bonanni, B., Guerrieri-Gonzaga, A., Gandini, S., Robertson, C., Johansson, H., Travaglini, R., Sandri, M. T., Tessadrelli, A., Farante, G., Salinaro, F., Bettega, D., Barreca, A., Boyle, P., Costa, A., and Veronesi, U. Biologic activity of tamoxifen at low doses in healthy women. J. Natl. Cancer Inst. (Bethesda), 90: 1461-1467, 1998.
70. Howe, L. R., Subbaramaiah, K., Patel, J., Masferrer, J. L., Deora, A., Hudis, C., Thaler, H. T., Muller, W. J., Du, B., Brown, A. M., and Dannenberg, A. J. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res., 62: 5405-5407, 2002.
71. Mao, L., Lee, J. S., Kurie, J. M., Fan, Y. H., Lippman, S. M., Lee, J. J., Ro, J. Y., Broxson, A., Yu, R., Morice, R. C., Kemp, B. L., Khuri, F. R., Walsh, G. L., Hittelman, W. N., and Hong, W. K. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. (Bethesda). 89: 857-862, 1997.
72. Kurie, J. M., Lotan, R., Lee, J. J., Lee, J. S., Morice, R. C., Liu, D. D., Xu, X. C., Khuri, F. R., Ro, J. Y., Hittelman, W. N., Walsh, G. L., Roth, J. A., Minna, J. D., and Hong, W. K. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J. Natl. Cancer Inst. (Bethesda), 95: 206-214, 2003.
73. Wattenberg, L. W., Wiedmann, T. S., Estensen, R. D., Zimmerman, C. L., Galbraith, A. R., Steele, V. E., and Kelloff, G. J. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis (Lond.), 21: 179-182, 2000.
74. Shureiqi, I., and Lippman, S. M. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res., 61: 6307-6312, 2001.
75. Xu, X-C., Shappell, S. B., Liang, Z., Song, S., Menter, D., Subbarayan, V., Iyengar, S., Tang, D. G., and Lippman, S. M. Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor NS398. Neoplasia, 5: 121-127, 2003.
76. Ford, L. G., Minasian, L. M., McCaskill-Stevens, W., Pisano, E. D., Sullivan, D., and Smith, R. A. Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA Cancer J. Clin., 53: 82-101, 2003.
77. Waters, D. J., Shen, S., Cooley, D. M., Bostwick, D. G., Qian, J., Combs, G. F., Jr., Glickman, L. T., Oteham, C., Schlittler, D., and Morris, J. S. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J. Natl. Cancer Inst. (Bethesda), 95: 237-241, 2003.
78. Hoque, A., Albanes, D., Lippman, S. M., Spitz, M. R., Taylor, P. R., Klein, E. A., Thompson, I. M., Goodman, P., Stanford, J. L., Crowley, J. J., Coltman, C. A., and Santella, R. M. Molecular epidemiologic studies within the selenium and vitamin E cancer prevention trial (SELECT). Cancer Causes and Control. 12: 627-633, 2001.
79. Schottenfeld, D. Principles and applications of cancer prevention. In: D. Schottenfeld and J. F. Fraumeni, Jr. (eds.), Cancer Epidemiology and Prevention. Ed. 2, pp. 1391-1409. New York, NY: Oxford University Press, 1996.
80. Herrington, D. M., and Howard, T. D. From presumed benefit to potential harm-hormone therapy and heart disease. N. Engl. J. Med., 349: 519-521, 2003.
81. Hursting, S. D., Lavigne, J. A., Berrigan, D., Perkins, S. N., and Barrett, J. C. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Ann. Rev. Med., 54: 131-152, 2003.
82. Calle, E. E., Rodriguez, C., Walker-Thurmond, K., and Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 348: 1625-1638, 2003.
83. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science (Wash. DC), 279: 563-566, 1998.
84. Peters, U., Sinha, R., Chatterjee, N., Subar, A. F., Ziegler, R. G. Kulldorff, M., Bresalier, R., Weissfeld, J. L., Flood, A., Schatzkin, A., Hayes, R. B., Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Dietary fibre and colorectal adenoma in colorectal cancer early detection programme. Lancet. 361: 1491-1495, 2003.
85. Alberts, D. S., Martinez, M. E., Roe, D. J., Guillen-Rodriguez, J. M., Marshall, J. R. van Leeuwen, J. B., Reid, M. E., Ritenbaugh, C., Vargas, P. A., Bhattacharyya, A. B., Earnest, D. L., Sampliner, R. E., and the Phoenix Colon Cancer Prevention Physicians' Network. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N. Engl. J. Med., 342: 1156-1162, 2000.
86. Schatzkin, A., Lanza, E., Corle, D., Lance, P., Iber, F., Caan, B., Shike, M., Weissfeld, J., Burt, R., Cooper, M. R., Kikendall, J. W., Cahill, J., and the Polyp Prevention Trial Study Group. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. N. Engl. J. Med., 342: 1149-1155, 2000.
87. Peto, R., Chen, Z. M., and Boreham, J. Tobacco-the growing epidemic. Nat. Med., 5: 15-17, 1999.
88. Spitz, M. R., Shi, H., Yang, F., Hudmon, K. S., Jiang, H., Chamberlain, R. M., Amos, C. I., Wan, Y., Cinciripini, P., Hong, W. K., and Wu, X. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J. Natl. Cancer Inst. (Bethesda), 90: 358-363, 1998.
89. Lerman, C., and Berrettini, W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am. J. Med. Genet., 118B: 48-54, 2003.
90. Shields, P. G., Lerman, C., Audrain, J., Bowman, E. D., Main, D., Boyd, N. R., and Caporaso, N. E. Dopamine D4 receptors and the risk of cigarette smoking in African Americans and Caucasians. Cancer Epidemiol. Biomark. Prev., 7: 453-458, 1998.
91. Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Pinto, A., Hawk, L., Krishnan, S., Niaura, R., and Epstein, L. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics, 12: 627-634, 2002.
92. Crabbe, J. C. Alcohol and genetics: new models. Am. J. Med. Genet, 114: 969-974, 2002.
93. Epstein, L. H., Jaroni, J. L., Paluch, R. A., Leddy, J. J., Vahue, H. E., Hawk, L., Wileyto, E. P., Shields, P. G., and Lerman, C. Dopamine transporter genotype as a risk factor for obesity in African-American smokers. Obes. Res., 10: 1232-1240, 2002.
94. Gritz, E. R., Prokhorov, A. V., Hudmon, K. S., Chamberlain, R. M., Taylor, W. C., DiClemente, C. C., Johnston, D. A., Hu, S., Jones, L. A., Jones, M. M., Rosenblum, C. K., Ayars, C. L., and Amos, C. I. Cigarette smoking in a multiethnic population of youth: methods and baseline findings. Prev. Med., 27: 365-384, 1998.
95. Bowen, D. J. Taste and food preference changes across the course of pregnancy. Appetite, 19: 233-242, 1992.
96. Adams-Campbell, L. L., Rosenberg, L., Washburn, R. A., Rao, R. S., Kim, K. S., and Palmer, J. Descriptive epidemiology of physical activity in African-American women. Prev. Med., 30: 43-50, 2000.
97. Bluman, L. G., Rimer, B. K., Berry, D. A., Borstelmann, N., Iglehart, J. D., Regan, K., Schildkraut, J., and Winer, E. P. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J. Clin. Oncol., 17: 1040-1046, 1999.
98. Geller, G., Bernhardt, B. A., Helzlsouer, K., Holtzman, N. A., Stefanek, M., and Wilcox, P. M. Informed consent and BRCA1 testing. Nat. Genet., 11: 364, 1995.
99. Skinner, C. S., Schildkraut, J. M., Berry, D., Calingaert, B., Marcom, P. K., Sugarman, J. P. A., and Rimer, B. K. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet. Test., 6: 93-105, 2002.
100. Schwartz, M. D., Peshkin, B. N., Hughes, C., Main, D., Isaacs, C., and Lerman, C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J. Clin. Oncol., 20: 514-520, 2002.
101. Costalas, J. W., Itzen, M., Malick, J., Babb, J. S., Bove, B., Godwin, A. K., and Daly, M. B. Communication of BRCA1 and BRCA2 results to at-risk relatives: a caner risk assessment program's experience. Am. J. Med. Genet., 119: 11-18, 2003.
102. Bowen, D. J., Patenaude, A. F., and Vernon, S. W. Psychosocial issues in cancer genetics: from the laboratory to the public. Cancer Epidemiol. Biomark. Prev., 8: 326-328, 1999.
103. Vernon, S. W., Gritz, E. R., Peterson, S. K., Amos, C. I., Baile, W. F., Perz, C. A., and Lynch, P. M. Design and methodology of a study of psychosocial aspects of genetic testing for hereditary colorectal cancer. Ann. N. Y. Acad. Sci., 833: 190-194, 1997.
104. Botkin, J. R., Smith, K. R., Croyle, R. T., Baty, B. J., Wylie, J. E., Dutson, D., Chan, A., Hamann, H. A., Lerman, C., McDonald, J., Venne, V., Ward, J. H., and Lyon, E. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am. J. Med. Genet., 118: 201-209, 2003.
105. Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J., Lynch, P., McTiernan, A., Offit, K., Perlman, J., Petersen, G., Thomson, E., and Varricchio, C. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. J. Am. Med. Assoc., 277: 997-1003, 1997.
106. Burke, W., Petersen, G., Lynch, P., Botkin, J., Daly, M., Garber, J., Kahn, M. J., McTiernan, A., Offit, K., Thomson, E., and Varricchio, C. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. J. Am. Med. Assoc., 277: 915-919, 1997.
107. McBride, C. M., Bepler, G., Lipkus, I. M., Lyna, P., Samsa, G., Albright, J., Datta, S., and Rimer, B. K. Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol. Biomark. Prev., 11: 521-528, 2002.
108. Audrain, J., Gomez-Caminero, A. Robertson, A. R., Boyd, R., Orleans, C. T., and Lerman, C. Gender and ethnic differences in readiness to change smoking behavior. Womens Health, 3: 139-150, 1997.
109. Helmes, A. W., Bowen, D. J., Bowden, R., and Bengel, J. Predictors of participation in genetic research in a primary care physician network. Cancer Epidemiol. Biomark. Prev., 9: 1377-1379, 2000.
110. Gotay, C. C., Moinpour, C. M., Moody-Thomas, S., Gritz, E. R., Albain, K. S., DeAntoni, E., Hansen, L., and Ganz, P. A. Behavioral science research in the cooperative group setting: the Southwest Oncology Group experience. J. Natl. Cancer Inst., 92: 1381-1387, 2000.
111. Ho, S. M., Ho, J. W., Chan, C. L., Kwan, K., and Tsui, Y. K. Decisional consideration of hereditary colon cancer genetic test results among Hong Kong Chinese adults. Cancer Epidemiol. Biomark. Prev., 12: 426-432, 2003.
112. Pignone, M., Saha, S., Hoerger, T., and Mandelblatt, J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U. S. Preventive Services Task Force. Ann. Intern. Med., 137: 96-104, 2002.
113. Day, R., Ganz, P. A., Costantino, J. P., Cronin, W. M., Wickerham, D. L., and Fishers, B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Clin. Oncol., 17: 2659-2669, 1999.
114. Geller, G., Bernhardt, B. A., Doksum, T., Helzlsouer, K. J., Wilcox, P., and Holtzman, N. A. Decision-making about breast cancer susceptibility testing: how similar are the attitudes of physicians, nurse practitioners, and at-risk women? J. Clin. Oncol., 16: 2868-2876, 1998.
115. Moinpour, C. M., Atkinson, J. O., Thomas, S. M., Underwood, S. M., Harvey, C., Parzuchowski, J., Lovato, L. C., Ryan, A. M., Hill, M. S., Deantoni, E., Gritz, E. R., Thompson, I. M., Jr., and Coltman, C. A., Jr. Minority recruitment in the prostate cancer prevention trial. Ann. Epidemiol., 10: S85-S91, 2000.
116. ATAC (Arimidex. Tamoxifen, Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359: 2131-2139, 2002.
117. Lippman, S. M., Lee, J. J., Karp, D. D., Vokes, E. E., Benner, S. E., Goodman, G. E., Khuri, F. R., Marks, R., Winn, R. J., Fry, W., Graziano, S. L., Gandara, D. R., Okawara, G., Woodhouse, C. L., Williams, B., Perez, C., Kim, H. W., Lotan, R., Roth, J. A., and Hong, W. K. Randomized Phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. (Bethesda), 93: 605-618, 2001.
118. Virtamo, J., Pietinen, P., Huttunen, J. K., Korhonen, P., Malila, N., Virtanen, M. J., Albanes, D., Taylor, P. R., Albert, P., ATBC Study Group. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. J. Am. Med. Assoc., 290: 476-485, 2003.
119. Lee, J. J., Hong, W. K., Hittelman, W. N., Mao, L., Lotan, R., Shin, D. M., Benner, S. E., Xu, X. C., Lee, J. S., Papadimitrakopoulou, V. M., Geyer, C., Perez, C., Martin, J. W., El-Naggar, A. K., and Lippman, S. M. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin. Cancer Res., 6: 1702-1710, 2000.
120. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., and Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med., 9: 213-219, 2003.
121. Coussens, L. M., and Werb, Z. Inflammation and cancer. Nature (Lond.), 420: 860-867, 2002.
122. Waldman, A., and Kritharides, L. The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs, 63: 139-152, 2003.
123. Girnun, G. D., Smith, W. M., Drori, S., Sarraf, P., Mueller, E., Eng, C., Nambiar, P., Rosenberg, D. W., Bronson, R. T., Edelmann, W., Kucherlapati, R., Gonzalez, F. J., and Spiegelman, B. M. APC-dependent suppression of colon carcinogenesis by PPAR-γ. Proc. Natl. Acad. Sci. USA, 99: 13771-13776, 2002.
124. Chan, K. K. W., Oza, A. M., and Siu, L. L. The statins as anticancer agents. Clin. Cancer Res., 9: 10-19, 2003.
125. Salas, T. R., Reddy, S. A., Clifford, J. L., Davis, R. J., Kikuchi, A., Lippman, S. M., and Menter, D. G. Alleviating the suppression of glycogen synthase kinase-3β by Akt leads to the phosphorylation of CREB and its transactivation in intact cell nuclei. J. Biol. Chem, in press, 2003.
126. Hong, W. K., and Sporn, M. B. Recent advances in chemoprevention of cancer. Science (Wash. DC), 278: 1073-1077, 1997.
127. Edwards, B. K., Howe, H. L., Ries, L. A. G., Thun, M. J., Rosenberg, H. M., Yancik, R., Wingo, P. A., Jemal, A., and Feigal, E. G. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U. S. cancer burden. Cancer (Phila.), 94: 2766-2792, 2002.
128. Lippman, S. M., and Hong, W. K. Cancer prevention science and practice. Cancer Res., 62: 5119-5125, 2002.